Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis

De Oliveira,Ligia  Petrolini; López,Ignacio; Dos Santos,Erika Maria Monteiro; Tucci,Paula; Marín,Mónica; Soares,Fernando Augusto; Rossi,Benedito Mauro; Coudry,Renata De Almeida

doi:10.3892/or.2013.2940

Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis

Authors:
- Ligia Petrolini De Oliveira
- Ignacio López
- Erika Maria Monteiro Dos Santos
- Paula Tucci
- Mónica Marín
- Fernando Augusto Soares
- Benedito Mauro Rossi
- Renata De Almeida Coudry
View Affiliations

Affiliations: Department of Anatomic Pathology, International Center for Research (CIPE) in Oncology, A.C. Camargo Cancer Center, São Paulo, SP, CEP 01508-010, Brazil, Department of Biochemistry, Faculty of Science, Universidad de la República, Montevideo CEP 11400, Uruguay
Published online on: December 20, 2013 https://doi.org/10.3892/or.2013.2940
Pages: 1396-1406

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TP53 represents a suitable candidate for a colorectal cancer susceptibility locus. The polymorphism in the p53 72nd codon involves a proline to arginine substitution, leading to changes in gene transcription activity, interaction with other proteins and modulation of apoptosis. Studies evaluating the association between this polymorphism and colorectal cancer (CRC) have shown inconsistent results, and none have evaluated the mRNA status of TP53. The aim of the present study was to evaluate the association between this SNP expression at the mRNA level in CRC samples and patient clinicopathological variables and prognosis, p53 protein expression and TP53 mutation. This is the first report to describe the mRNA expression of p53 codon 72 alleles in CRC. We evaluated 101 non-related patients with CRC treated at the A.C. Camargo Cancer Center in Brazil. RNA was isolated from frozen tumor tissues using a trizol-based protocol. The polymorphism was detected using RT-PCR followed by Sanger sequencing. Associations were analyzed using Pearson's Chi-square or Fisher's exact tests, logistic regression and Cox. This polymorphism was significantly associated with clinicopathological variables related to increased tumor aggressiveness. The expression of Arg72 (OR, 3.83; CI 1.02-14.35; P=0.046) and the TNM stage (OR, 7.15; CI 1.45-35.29; P=0.016) were found to be independent predictors for recurrence. These data suggest that the mRNA expression of the Pro72 allele is associated with less favorable tumor features. The allele frequency of the p53 Pro72 was 0.26. The analysis of mRNA is important to determine the specific contribution of the allele expressed. These results suggest that this polymorphism may play a role in CRC.

View Figures

View References

1	Tang NP, Wu YM, Wang B, et al: Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol. 36:431–438. 2010. View Article : Google Scholar : PubMed/NCBI
2	Valentin MD, da Silva FC, dos Santos EM, et al: Characterization of germline mutations of MLH1 and MSH2 in unrelated South American suspected Lynch syndrome individuals. Fam Cancer. 10:641–647. 2011. View Article : Google Scholar : PubMed/NCBI
3	da Silva FC, de Oliveira LP, Santos EM, et al: Frequency of extracolonic tumors in Brazilian families with Lynch syndrome: analysis of a hereditary colorectal cancer institutional registry. Fam Cancer. 9:563–570. 2010.PubMed/NCBI
4	Stadler ZK, Vijai J, Thom P, et al: Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am. 24:973–996. 2010. View Article : Google Scholar : PubMed/NCBI
5	Fearon ER and Vogelstein B: A genetic model for colorectal tumorigenesis. Cell. 61:759–767. 1990. View Article : Google Scholar : PubMed/NCBI
6	Hollstein M and Hainaut P: Massively regulated genes: the example of TP53. J Pathol. 220:164–173. 2010.PubMed/NCBI
7	Shi H, Tan SJ, Zhong H, et al: Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia. Am J Hum Genet. 84:534–541. 2009. View Article : Google Scholar : PubMed/NCBI
8	Mammano E, Belluco C, Bonafé M, et al: Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol. 35:415–419. 2009. View Article : Google Scholar : PubMed/NCBI
9	The International HapMap Consortium. The International HapMap Project. Nature. 426:789–796. 2003. View Article : Google Scholar
10	Marin MC, Jost CA, Brooks LA, et al: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet. 25:47–54. 2000. View Article : Google Scholar : PubMed/NCBI
11	Millau JF, Bastien N and Drouin R: P53 transcriptional activities: a general overview and some thoughts. Mutat Res. 681:118–133. 2009. View Article : Google Scholar : PubMed/NCBI
12	Hu Z, Li X, Yuan R, et al: Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat. 120:705–714. 2010.
13	Siddique MM, Balram C, Fiszer-Maliszewska L, et al: Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol Biomarkers Prev. 14:2245–2252. 2005. View Article : Google Scholar : PubMed/NCBI
14	Song HR, Kweon SS, Kim HN, et al: p53 codon 72 polymorphism in patients with gastric and colorectal cancer in a Korean population. Gastric Cancer. 14:242–248. 2011. View Article : Google Scholar : PubMed/NCBI
15	Cañas M, Morán Y, Camargo ME, et al: TP53 codon 72 polymorphism and gastric cancer risk: a case-control study in individuals from the central-western region of Venezuela. Invest Clin. 50:153–161. 2009.(In Spanish).
16	Rogounovitch TI, Saenko VA, Ashizawa K, et al: TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer. Oncol Rep. 15:949–956. 2006.
17	Granja F, Morari J, Morari EC, et al: Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 210:151–157. 2004. View Article : Google Scholar : PubMed/NCBI
18	Piao JM, Kim HN, Song HR, et al: p53 codon 72 polymorphism and the risk of lung cancer in a Korean population. Lung Cancer. 73:264–267. 2011. View Article : Google Scholar : PubMed/NCBI
19	Dai S, Mao C, Jiang L, et al: P53 polymorphism and lung cancer susceptibility: a pooled analysis of 32 case-control studies. Hum Genet. 125:633–638. 2009. View Article : Google Scholar : PubMed/NCBI
20	Rosenthal AN, Ryan A, Hopster D, et al: p53 codon 72 polymorphism in vulval cancer and vulval intraepithelial neoplasia. Br J Cancer. 83:1287–1290. 2000. View Article : Google Scholar : PubMed/NCBI
21	Lin HY, Huang CH, Yu TJ, et al: p53 codon 72 polymorphism as a progression index for bladder cancer. Oncol Rep. 27:1193–1199. 2012.PubMed/NCBI
22	Li DB, Wei X, Jiang LH, et al: Meta-analysis of epidemiological studies of association of P53 codon 72 polymorphism with bladder cancer. Genet Mol Res. 9:1599–1605. 2010. View Article : Google Scholar : PubMed/NCBI
23	Sousa H, Santos AM, Pinto D, et al: Is there a biological plausability for p53 codon 72 polymorphism influence on cervical cancer development? Acta Med Port. 24:127–134. 2011.PubMed/NCBI
24	Klug SJ, Ressing M, Koenig J, et al: TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol. 10:772–784. 2009. View Article : Google Scholar : PubMed/NCBI
25	Li MS, Liu JL, Wu Y, et al: Meta-analysis demonstrates no association between p53 codon 72 polymorphism and prostate cancer risk. Genet Mol Res. 10:2924–2933. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhu Y, Wang J, He Q, et al: Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis. Mol Biol Rep. 38:1603–1607. 2011. View Article : Google Scholar : PubMed/NCBI
27	Tang W, He X, Chan Y, et al: Lack of association between p53 codon 72 polymorphism and endometrial cancer: a meta-analysis. Cancer Epidemiol. 36:153–157. 2012. View Article : Google Scholar : PubMed/NCBI
28	Zubor P, Stanclova A, Kajo K, et al: The p53 codon 72 exon 4 BstUI polymorphism and endometrial cancer in Caucasian women. Oncology. 76:173–183. 2009. View Article : Google Scholar : PubMed/NCBI
29	Suresh K, Chandirasekar R, Kumar BL, et al: No association between the Trp53 codon 72 polymorphism and head and neck cancer: a case-control study in a South Indian population. Asian Pac J Cancer Prev. 11:1749–1753. 2010.PubMed/NCBI
30	Mojtahedi Z, Hashemi SB, Khademi B, et al: p53 codon 72 polymorphism association with head and neck squamous cell carcinoma. Braz J Otorhinolaryngol. 76:316–320. 2010.PubMed/NCBI
31	Själander A, Birgander R, Athlin L, et al: P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis. 16:1461–1464. 1995.PubMed/NCBI
32	Gemignani F, Moreno V, Landi S, et al: A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene. 23:1954–1956. 2004.
33	Goodman JE, Mechanic LE, Luke BT, et al: Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer. 118:1790–1797. 2006. View Article : Google Scholar : PubMed/NCBI
34	Pérez LO, Abba MC, Dulout FN, et al: Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol. 12:1426–1429. 2006.PubMed/NCBI
35	Zhu ZZ, Wang AZ, Jia HR, et al: Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol. 37:385–390. 2007.
36	Dakouras A, Nikiteas N, Papadakis E, et al: p53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res. 28:1039–1043. 2008.
37	Koushik A, Tranah GJ, Ma J, et al: p53 Arg72Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer. 119:1863–1868. 2006. View Article : Google Scholar : PubMed/NCBI
38	Tan XL, Nieters A, Hoffmeister M, et al: Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics. 17:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
39	Hase K, Shatney C, Johnson D, et al: Prognostic value of tumor ‘budding’ in patients with colorectal cancer. Dis Colon Rectum. 36:627–635. 1993.
40	López I, Oliveira PL, Tucci P, et al: Different mutation profiles associated to P53 accumulation in colorectal cancer. Gene. 499:81–87. 2012.PubMed/NCBI
41	Goldstein DB: The importance of synthetic associations will only be resolved empirically. PLoS Biol. 9:e10010082011. View Article : Google Scholar : PubMed/NCBI
42	Anderson CA, Soranzo N, Zeggini E, et al: Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol. 9:e10005802011. View Article : Google Scholar : PubMed/NCBI
43	Wray NR, Purcell SM and Visscher PM: Synthetic associations created by rare variants do not explain most GWAS results. PLoS Biol. 9:e10005792011. View Article : Google Scholar : PubMed/NCBI
44	Orozco G, Barrett JC and Zeggini E: Synthetic associations in the context of genome-wide association scan signals. Hum Mol Genet. 19:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
45	Shields R: Common disease: are causative alleles common or rare? PLoS Biol. 9:e10010092011. View Article : Google Scholar : PubMed/NCBI
46	Ritchie MD: Using biological knowledge to uncover the mystery in the search for epistasis in genome-wide association studies. Ann Hum Genet. 75:172–182. 2011. View Article : Google Scholar : PubMed/NCBI
47	Dickson SP, Wang K, Krantz I, et al: Rare variants create synthetic genome-wide associations. PLoS Biol. 8:e10002942010. View Article : Google Scholar : PubMed/NCBI
48	Yan H, Yuan W, Velculescu VE, et al: Allelic variation in human gene expression. Science. 297:11432002. View Article : Google Scholar : PubMed/NCBI
49	Bray NJ, Buckland PR, Owen MJ, et al: Cis-acting variation in the expression of a high proportion of genes in human brain. Hum Genet. 113:149–153. 2003.
50	Lo HS, Wang Z, Hu Y, et al: Allelic variation in gene expression is common in the human genome. Genome Res. 13:1855–1862. 2003.PubMed/NCBI
51	Schadt EE, Monks SA, Drake TA, et al: Genetics of gene expression surveyed in maize, mouse and man. Nature. 422:297–302. 2003. View Article : Google Scholar : PubMed/NCBI
52	Pastinen T, Sladek R, Gurd S, et al: A survey of genetic and epigenetic variation affecting human gene expression. Physiol Genomics. 16:184–193. 2004. View Article : Google Scholar : PubMed/NCBI
53	Cheung VG, Bruzel A, Burdick JT, et al: Monozygotic twins reveal germline contribution to allelic expression differences. Am J Hum Genet. 82:1357–1360. 2008. View Article : Google Scholar : PubMed/NCBI
54	Gimelbrant A, Hutchinson JN, Thompson BR, et al: Widespread monoallelic expression on human autosomes. Science. 318:1136–1140. 2007. View Article : Google Scholar : PubMed/NCBI
55	Thomas M, Kalita A, Labrecque S, et al: Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol. 19:1092–1100. 1999.PubMed/NCBI
56	Dumont P, Leu JI, Della Pietra AC III, et al: The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 33:357–365. 2003. View Article : Google Scholar : PubMed/NCBI
57	Ozeki C, Sawai Y, Shibata T, et al: Cancer susceptibility polymorphism of p53 at codon 72 affects phosphorylation and degradation of p53 protein. J Biol Chem. 286:18251–18260. 2011. View Article : Google Scholar : PubMed/NCBI
58	Hancox RJ, Poulton R, Welch D, et al: Accelerated decline in lung function in cigarette smokers is associated with TP53/MDM2 polymorphisms. Hum Genet. 126:559–565. 2009. View Article : Google Scholar : PubMed/NCBI
59	Pandith AA, Shah ZA, Khan NP, et al: Role of TP53 Arg72Pro polymorphism in urinary bladder cancer predisposition and predictive impact of proline related genotype in advanced tumors in an ethnic Kashmiri population. Cancer Genet Cytogenet. 203:263–268. 2010.
60	Tobacco Free Initiative (TFI). WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco. World Health Organization; 2011, Available at http://www.who.int/tobacco/global_report/2011/en/.
61	Marqueta A, Nerín I, Jiménez-Muro A, et al: Predictors of outcome of a smoking cessation treatment by gender. Gac Sanit. 27:23–31. 2012.(In Spanish).
62	Hiscock R, Bauld L, Amos A, et al: Socioeconomic status and smoking: a review. Ann NY Acad Sci. 1248:107–123. 2012. View Article : Google Scholar : PubMed/NCBI
63	Norppa H: Cytogenetic biomarkers and genetic polymorphisms. Toxicol Lett. 149:309–334. 2004. View Article : Google Scholar : PubMed/NCBI
64	Vodicka P, Kumar R, Stetina R, et al: Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA. Carcinogenesis. 25:757–763. 2004. View Article : Google Scholar : PubMed/NCBI
65	Hanova M, Vodickova L, Vaclavikova R, et al: DNA damage, DNA repair rates and mRNA expression levels of cell cycle genes (TP53, p21^CDKN1A, BCL2 and BAX) with respect to occupational exposure to styrene. Carcinogenesis. 32:74–79. 2011. View Article : Google Scholar : PubMed/NCBI
66	Jass JR, Love SB and Northover JM: A new prognostic classification of rectal cancer. Lancet. 1:1303–1306. 1987. View Article : Google Scholar : PubMed/NCBI
67	Zlobec I, Baker K, Minoo P, et al: Tumor border configuration added to TNM staging better stratifies stage II colorectal cancer patients into prognostic subgroups. Cancer. 115:4021–4029. 2009. View Article : Google Scholar : PubMed/NCBI
68	Zlobec I, Terracciano LM and Lugli A: Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8⁺ tumor-infiltrating lymphocytes. Clin Cancer Res. 14:3792–3797. 2008. View Article : Google Scholar : PubMed/NCBI
69	Grochola LF, Zeron-Medina J, Mériaux S, et al: Single-nucleotide polymorphisms in the p53 signaling pathway. Cold Spring Harb Perspect Biol. 2:a0010322010. View Article : Google Scholar : PubMed/NCBI
70	Wilkinson NW: Adjuvant chemotherapy for colorectal cancer-new perspectives for effective treatment. US Gastroenterol Hepatol Rev. 1:91–93. 2007.
71	Casillas S, Pelley RJ and Milsom JW: Adjuvant therapy for colorectal cancer: present and future perspectives. Dis Colon Rectum. 40:977–992. 1997. View Article : Google Scholar : PubMed/NCBI
72	Fuchs CS and Mayer RJ: Adjuvant chemotherapy for colon and rectal cancer. Semin Radiat Oncol. 3:29–41. 1993. View Article : Google Scholar : PubMed/NCBI
73	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
74	Naccarati A, Polakova V, Pardini B, et al: Mutations and polymorphisms in TP53 gene: an overview on the role in colorectal cancer. Mutagenesis. 27:211–218. 2012.
75	Sullivan A, Syed N, Gasco M, et al: Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene. 23:3328–3337. 2004. View Article : Google Scholar : PubMed/NCBI
76	Pim D and Banks L: p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer. 108:196–199. 2004. View Article : Google Scholar : PubMed/NCBI
77	Bergamaschi D, Samuels Y, Sullivan A, et al: iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53. Nat Genet. 38:1133–1141. 2006. View Article : Google Scholar : PubMed/NCBI
78	Nelson HH, Wilkojmen M, Marsit CJ, et al: TP53 mutation, allelism and survival in non-small cell lung cancer. Carcinogenesis. 26:1770–1773. 2005. View Article : Google Scholar : PubMed/NCBI
79	Tommiska J, Eerola H, Heinonen M, et al: Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res. 11:5098–5103. 2005. View Article : Google Scholar : PubMed/NCBI
80	Xu Y, Yao L, Ouyang T, et al: p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res. 11:7328–7333. 2005. View Article : Google Scholar : PubMed/NCBI
81	Petitjean A, Mathe E, Kato S, et al: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 28:622–629. 2007.PubMed/NCBI
82	Bougeard G, Baert-Desurmont S, Tournier I, et al: Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet. 43:531–533. 2006.